Targeting peptidylarginine deiminases 2 and 4 in diabetic kidney disease: mechanistic rationale and preclinical evidence.
- DOI
- 10.1016/j.bcp.2026.118396
- Published
- 2026 Aug 26
- Container
- Biochemical pharmacology
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.bcp.2026.118396,
title = {Targeting peptidylarginine deiminases 2 and 4 in diabetic kidney disease: mechanistic rationale and preclinical evidence.},
author = {Mallek W and Wróblewska-Schmude A and Lesner A and Piwkowska A and Wysocka M},
year = {2026},
journal = {Biochemical pharmacology},
doi = {10.1016/j.bcp.2026.118396},
url = {https://doi.org/10.1016/j.bcp.2026.118396}
}RIS
TY - JOUR TI - Targeting peptidylarginine deiminases 2 and 4 in diabetic kidney disease: mechanistic rationale and preclinical evidence. AU - Mallek W AU - Wróblewska-Schmude A AU - Lesner A AU - Piwkowska A AU - Wysocka M PY - 2026 JO - Biochemical pharmacology DO - 10.1016/j.bcp.2026.118396 UR - https://doi.org/10.1016/j.bcp.2026.118396 ER -
APA
W, M., A, W., A, L., A, P., & M, W. (2026). Targeting peptidylarginine deiminases 2 and 4 in diabetic kidney disease: mechanistic rationale and preclinical evidence.. Biochemical pharmacology. https://doi.org/10.1016/j.bcp.2026.118396
Source records
- pubmed · retrieved 2026-09-26T10:06:25.828Z